Solventum Corporation (SOLV)
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.
Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript
Solventum Corporation (NYSE:SOLV ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan C. Hanson - CEO & Director Wayde D.
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Solventum (SOLV) Beats Q2 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.56 per share a year ago.
Solventum raises annual profit forecast on strength in surgical equipment
Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses.
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
Ahead of Solventum (SOLV) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Solventum (SOLV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Solventum: Appealing Again
Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimated at $5.50-$6.00 and leverage much lower post-divestment.
Is the Options Market Predicting a Spike in Solventum Stock?
Investors need to pay close attention to SOLV stock based on the movements in the options market lately.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Solventum (SOLV) Just Overtook the 200-Day Moving Average
Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a long-term bullish trend.
